Longeveron News and Activities

Longeveron is a company listed under the stock ticker LGVN (US).

View the org chart displaying its 19 main executives

Most searched biographies at Longeveron

• Stephen Willard, Chief Executive Officer
• Rock Soffer, Director
• Ursula Ungaro, Director

Popular executive movements at Longeveron

• Marie Washburn will join the company as Chief Financial Officer on Jul. 13, 2026  (posted on July 7 2026).
• Lisa Locklear, Executive Vice President and Chief Financial Officer, will leave the company on Jul. 13, 2026  (posted on July 7 2026).
• Stephen Willard has joined the company as Chief Executive Officer  (posted on February 18 2026).

Create your alert
to follow the executive moves at Longeveron.

Longeveron has 2,428 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Longeveron

• Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
• Longeveron® Appoints Marie Washburn as Chief Financial Officer
• New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
• Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
• Longeveron to Present at BIO International Convention 2026
• Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
• Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
• Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
• Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
• Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
• View more press releases Close

Social media about Longeveron

• Longeveron on Wikipedia, Google News & Yahoo Finance
• Longeveron on LinkedIn, X (Twitter) & YouTube